Journals / Endokrinolojide Diyalog Dergisi / 2011 / Cilt: 8 - Sayı: 4

Testosterone and cardiovascular risk

Testosteron ve kardiyovasküler risk

Pages
177–180
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This paper attempts to present a review of the relevant literature on the effects of testosterone on the cardiovascular system.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The effects of androgens on cardiovascular pathophysiology have not yet been completely clarified.
📊
Key Findings & Data:These components are related with increased cardiovascular risk and mortality.
💡
Conclusion & Impact:This paper attempts to present a review of the relevant literature on the effects of testosterone on the cardiovascular system.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The effects of androgens on cardiovascular pathophysiology have not yet been completely clarified. It is known that many components of the metabolic syndrome such as obesity, dyslipidemia, diabetes mellitus and insulin resistance can be observed in hypogonadal men. These components are related with increased cardiovascular risk and mortality. Testosterone replacement therapy might be important in hypogonadal men in terms of decreasing cardiovascular risk. This paper attempts to present a review of the relevant literature on the effects of testosterone on the cardiovascular system.

Özet

Son yıllarda androjenlerin kardiyovasküler sistem üzerinde etkileri ile ilgili araştırmalar artmakla birlikte kardiyovasküler patofizyoloji üzerindeki etkileri tam olarak açıklanamamıştır. Metabolik sendromun obezite, dislipidemi, diabetes mellitus ve insülin rezistansı gibi birçok komponentinin hipogonad erkeklerde bulunduğu bilinmektedir. Bu komponentler artmış kardiyovasküler risk ile ilişkili olup mortaliteyi de artırmaktadır. Kesin kanıtları olmamakla birlikte testosteron replasman tedavisi kardiyovasküler riski azaltmak açısından özellikle hipogonad erkeklerde önemli olabilir. Bu derlemede testosteron ve kardiyovasküler etkileri ile ilgili literatür gözden geçirilmiştir.

🔖

Cite This Article

ARPACI, D., ERSOY, R. (2022). Testosterone and cardiovascular risk. Endokrinolojide Diyalog Dergisi, Cilt: 8 - Sayı: 4, 177–180. https://ajindex.com/articles/500756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1996;98:1699-1670
  2. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999;340:115-126
  3. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994;14:701-706
  4. Markmann P, Sandstrom B, Jespersen J. Favorable long-term effect of a low fat/high fiber diet on human blood coagulation and fibrinolysis. Arterioscler Thromb 1993;13:505-511
  5. Yang XC, Jing TY, Resnick LM, Phillips GB. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993;13:467-471
  6. Freedman DS, O’Brien TR, Flanders WD, DeStefano F, Barboriak JJ. Relation of serum testosteron levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler Thromb 1991;11:307-315
  7. Caron P, Bennet A, Camare Ri, Louvet JP, Boneu B, Sie P. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989;38:1010-1015
  8. Hamalainen E, Adlercreutz F, Ehnholm C, Puska P. Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 1986;35:535-541
  9. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 2000;24:59-63
  10. Kiel DP, Baron JA, Plymate SR, Chute JG. Sex hormones and lipoproteins in men. AM J Med 1989;35-39
  11. Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993;122:412-420
  12. Tsai EC, Boyko EG, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese- American men. Int J Obes Relat Metab Disord 2000;24:485-491
  13. Hergenc G, Schulte H, Assmann G, Von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 1999;145-147-156
  14. Tchernof A, Labrie F, Belanger A, Despres JP. Obesity and metabolic complications; contribution of dehydroepiandrosterone and other steroid hormones. J Endocrinol 1996;150:155-164
  15. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk